Understand the source comparison
Comparison Table: SS-LUP-332 vs Other Metabolic Research Compounds
Understanding where SS-LUP-332 sits within the broader landscape of metabolic peptides helps contextualize its pharmacokinetic profile. The table below compares half-life, dosing frequency, and practical research considerations across commonly used compounds i
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Understanding where SS-LUP-332 sits within the broader landscape of metabolic peptides helps contextualize its pharmacokinetic profile. The table below compares half-life, dosing frequency, and practical research considerations across commonly used compounds in metabolic and exercise mimetic research.
- SS-LUP-332
- 3–4 hours
- Twice daily (BID)
- AMPK activation, PPARδ agonism
- 48 hours
- Short half-life requires strict dosing adherence; best for protocols where frequent administration is feasible and plasma level consistency matters less than cumulative exposure
- Semaglutide
- ~7 days
- Once weekly
- GLP-1 receptor agonist, delays gastric emptying
- 4–6 weeks
- Long half-life simplifies compliance; ideal for longer-duration metabolic studies but complicates dose adjustments and requires extended washout
- Tirzepatide
- ~5 days
- Dual GIP/GLP-1 receptor agonist
- 3–4 weeks
- Similar benefits to semaglutide with dual incretin activity; weekly dosing reduces variability but limits flexibility in acute study designs
- AICAR
- 0.5–1 hour
- Multiple daily or continuous infusion
- Direct AMPK activator
- 12–24 hours
- Extremely short half-life makes it impractical for standard injection protocols; typically used in IV infusion models or ex vivo tissue studies
- GW501516 (Cardarine)
- 16–24 hours
- Once daily
- PPARδ agonist
- 5–7 days
- Longer half-life than SS-LUP-332 with overlapping PPARδ mechanism; once-daily dosing is more practical, but regulatory and safety concerns limit availability for research
- Metformin
- 4–6 hours
- Twice or three times daily
- Complex: AMPK activation, mitochondrial complex I inhibition
- 48–72 hours
- Comparable half-life to SS-LUP-332; well-established safety profile and extensive literature make it a reference standard, though mechanism is less selective
- The bottom line: SS-LUP-332 sits in an awkward middle ground. Short enough that once-daily dosing leaves large gaps in therapeutic coverage, but long enough that continuous infusion isn't necessary. For labs equipped to handle twice-daily dosing schedules and focused on mitochondrial or fatty acid metabolism endpoints, it's a precise tool. For studies prioritizing convenience or requiring weekly administration, longer-acting alternatives may be more practical.